arrow
I

Isaku Okamoto

Tokyo Medical University
H指数:21
被引数:1,299

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical outcomes and prognostic significance of endoscopic laryngo-pharyngeal surgery for head and neck squamous cell carcinoma: a retrospective analysis of 111 cases

内镜下喉咽部手术在头颈部鳞状细胞癌中的临床疗效及预后意义:111例病例的回顾性分析

2025-11-010
PRE
Summary of Japanese clinical practice guidelines for head and neck cancer-2025 update edited by the Japan Society for Head and Neck Cancer
2025-10-010
PRE
Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab

血液学标志物可预测接受帕博利珠单抗治疗的复发或转移性头颈部鳞状细胞癌患者的免疫相关不良事件

2025-09-010
PRE
The efficacy of ICIs plus platinum-based chemotherapy for patients with advanced NSCLC and ECOG PS 2 (WJOG18424L): A propensity score-matched study

ICIs联合铂类化疗对ECOG PS 2评分的晚期NSCLC患者的疗效(WJOG18424L):一项倾向性评分匹配研究

2024-12-010
PRE
Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling

通过综合分子谱分析鉴定涎腺导管癌的新型预后和预测生物标志物

2022-11-047
OAAI
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma

HER2-targeted或雄激素剥夺疗法在涎腺导管癌中的生存益处

2022-09-0619
OAAI
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy

EZH2和H3K27me3表达作为涎腺导管癌患者临床预后预测指标的作用: 一项大型系列研究,重点是雄激素阻断和HER2-Targeted联合治疗的相关性

2022-02-0315
OAAI
Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma

纳武利尤单抗治疗复发和转移性涎腺癌的疗效和安全性的多中心回顾性研究

2020-10-1231
OAAI
The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma

涎腺导管癌中adipophilin和脂肪酸合酶表达的临床病理意义

2020-02-269
OAAI